Literature DB >> 21513014

Hormone therapy dosing regimen affects development of castration resistance.

Sarah Payton.   

Abstract

Year:  2011        PMID： 21513014     DOI： 10.1038/nrurol.2011.5

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.

Authors:  Jeremy M Blumberg; Eric O Kwon; T Craig Cheetham; Fang Niu; Charles E Shapiro; Judith Pacificar; Ronald K Loo; Stephen G Williams; Gary W Chien
Journal:  Urology       Date:  2010-12-15       Impact factor: 2.649
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.